Ovid Therapeutics
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The Company’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE).
Check out an overview of our patient communities and learn about the disease areas in which we are committed to developing treatments.
109 articles with Ovid Therapeutics
-
Ovid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline Conference
6/6/2022
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, presented data at the 2022 Epilepsy Foundation Pipeline Conference.
-
Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights
5/10/2022
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today reported financial results and corporate highlights for the first quarter ended March 31, 2022.
-
Ovid Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
4/8/2022
Ovid Therapeutics Inc. today announced that management will present at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 12:45 p.m. ET.
-
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results
3/15/2022
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021.
-
Ovid Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference
3/4/2022
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people affected by epilepsies and rare neurological disorders, today announced that management will participate virtually in the “Orphan Neuro and Neuromuscular” panel discussion at the Cowen 42nd Annual Health Care Conference.
-
On Wednesday, Massachusetts-based ConforMIS said it was suspending all distribution of its orthopedic medical devices to Russia and any Russian-based entities.
-
On Sunday, Boehringer Ingelheim tweeted a message of support for Ukraine, and announced it was standing in solidarity with the embattled Eastern-European country.
-
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
-
Healx and Ovid Therapeutics to Enter Strategic Partnership
2/8/2022
Ovid Therapeutics announced that Healx has secured from Ovid an exclusive option to license rights to develop and commercialize gaboxadol. Under the agreement, Healx plans to investigate the compound as part of a potential combination therapy for Fragile X syndrome, as well as a treatment for other indications.
-
New York-based Ovid Therapeutics and Healx have entered a strategic partnership to investigate the compound gaboxadol to treat Fragile X Syndrome (FXS).
-
Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators
1/3/2022
Exclusive license from AstraZeneca adds a unique candidate and a broad library of compounds to Ovid’s franchise of potential first-in-class anti-epileptic therapies.
-
Data from pre-clinical studies show that OV350 may be developed to treat multiple types of epilepsy and other CNS conditions, including neurodevelopmental diseases.
-
Ovid Therapeutics Reports Third Quarter 2021 Business Update, Corporate Highlights and Financial Results
11/10/2021
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today provided a business update and reported corporate highlights and financial results for the quarter ended September 30, 2021.
-
BioSpace Movers & Shakers, Oct. 8
10/8/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Ovid Therapeutics Appoints Dr. Kevin Fitzgerald to Board of Directors
10/7/2021
Ovid Therapeutics Inc. today announced that it has appointed Kevin Fitzgerald, Ph.D., to its Board of Directors.
-
Ovid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
9/7/2021
Ovid Therapeutics Inc. today announced that management will present in a virtual format at the H.C. Wainwright 23rd Annual Global Investment Conference.
-
Ovid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights
8/16/2021
Ovid Therapeutics Inc. today reported financial results for the quarter ended June 30, 2021.
-
BioSpace’s Pharm Country Hotbed ranges from Connecticut, New York, New Jersey, Pennsylvania and Rhode Island.
-
This week's announcement includes a step to the side for CMO Amit Rakhit, who will transition to the biotech's advisory board.
-
Ovid Therapeutics Strengthens Board & Leadership Team to Focus Efforts on Expanding Its Neurosciences Capabilities
7/8/2021
Ovid Therapeutics Inc. (NASDAQ: OVID) today announced appointments to its board of directors and leadership team as well as a realignment of its workforce to focus on early-stage development activities, including the build out of its neuroscience programs